Researchers can use genome sequencing to figure out which microbes live in our guts or in the biofilms on our teeth or our implanted devices. But it’s much harder to figure out exactly where those microbes are, or how their distribution is changing over time. Kanvas’s founders invented a system that uses barcoded fluorescent probes and machine learning classification to map microbial communities in the gut and the mouth. The company plans to use the technique to find new ways to exploit the microbiome to improve health human, including developing novel therapeutics, understanding better how drugs are metabolized in the gut, and providing better diagnostic insights into infectious disease.
News & Insights
The Engineered Patient
With Assets from Federation Bio, Kanvas Aims to Replace Imprecise Microbiome Therapies with a Single, Rationally Designed Pill
DCVC leads $12M financing for Kanvas Biosciences to map the human body’s undiscovered territory: the microbiome
Explore Companies
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing